Acute Pustular Dermatosis, Following Topical Treatment With Pimecrolimus, in a Child Affected With Atopic and Contact Hand Dermatitis

Dimitri Poddighe, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia

Research output: Contribution to journalArticle

Abstract

Atopic dermatitis is considered an important risk factor for chronic hand dermatitis, which can be seen in children too. Pimecrolimus cream 1% is approved to treat atopic dermatitis in children aged 2 years or older. In adults, this drug has been used for some clinical indications other than atopic dermatitis, such as chronic hand dermatitis. Here, we describe an adverse drug reaction in a 2-year-old child affected with atopic dermatitis, who was treated with topical pimecrolimus in order to ameliorate her concomitant hand dermatitis. The use of topical pimecrolimus led to a previously undescribed hand pustular dermatosis, being consistent with a form of pustular leukocytoclastic vasculitis, which required the permanent discontinuation of topical pimecrolimus.

Original languageEnglish
Pages (from-to)81-4
Number of pages4
JournalJournal of Pediatric Pharmacology and Therapeutics
Volume21
Issue number1
DOIs
Publication statusPublished - Mar 22 2016
Externally publishedYes

Fingerprint

Contact Dermatitis
Atopic Dermatitis
Skin Diseases
Dermatitis
Hand
Hand Dermatoses
Therapeutics
Drug-Related Side Effects and Adverse Reactions
pimecrolimus
Pharmaceutical Preparations

Cite this

Acute Pustular Dermatosis, Following Topical Treatment With Pimecrolimus, in a Child Affected With Atopic and Contact Hand Dermatitis. / Poddighe, Dimitri; Brazzelli, Valeria; Licari, Amelia; Marseglia, Gian Luigi.

In: Journal of Pediatric Pharmacology and Therapeutics, Vol. 21, No. 1, 22.03.2016, p. 81-4.

Research output: Contribution to journalArticle

@article{7aff78a9e2be41a2ad8586a6447d3ea0,
title = "Acute Pustular Dermatosis, Following Topical Treatment With Pimecrolimus, in a Child Affected With Atopic and Contact Hand Dermatitis",
abstract = "Atopic dermatitis is considered an important risk factor for chronic hand dermatitis, which can be seen in children too. Pimecrolimus cream 1{\%} is approved to treat atopic dermatitis in children aged 2 years or older. In adults, this drug has been used for some clinical indications other than atopic dermatitis, such as chronic hand dermatitis. Here, we describe an adverse drug reaction in a 2-year-old child affected with atopic dermatitis, who was treated with topical pimecrolimus in order to ameliorate her concomitant hand dermatitis. The use of topical pimecrolimus led to a previously undescribed hand pustular dermatosis, being consistent with a form of pustular leukocytoclastic vasculitis, which required the permanent discontinuation of topical pimecrolimus.",
author = "Dimitri Poddighe and Valeria Brazzelli and Amelia Licari and Marseglia, {Gian Luigi}",
year = "2016",
month = "3",
day = "22",
doi = "10.5863/1551-6776-21.1.81",
language = "English",
volume = "21",
pages = "81--4",
journal = "Journal of Pediatric Pharmacology and Therapeutics",
issn = "1551-6776",
publisher = "Pediatric Pharmacology Advocacy Group, Inc.",
number = "1",

}

TY - JOUR

T1 - Acute Pustular Dermatosis, Following Topical Treatment With Pimecrolimus, in a Child Affected With Atopic and Contact Hand Dermatitis

AU - Poddighe, Dimitri

AU - Brazzelli, Valeria

AU - Licari, Amelia

AU - Marseglia, Gian Luigi

PY - 2016/3/22

Y1 - 2016/3/22

N2 - Atopic dermatitis is considered an important risk factor for chronic hand dermatitis, which can be seen in children too. Pimecrolimus cream 1% is approved to treat atopic dermatitis in children aged 2 years or older. In adults, this drug has been used for some clinical indications other than atopic dermatitis, such as chronic hand dermatitis. Here, we describe an adverse drug reaction in a 2-year-old child affected with atopic dermatitis, who was treated with topical pimecrolimus in order to ameliorate her concomitant hand dermatitis. The use of topical pimecrolimus led to a previously undescribed hand pustular dermatosis, being consistent with a form of pustular leukocytoclastic vasculitis, which required the permanent discontinuation of topical pimecrolimus.

AB - Atopic dermatitis is considered an important risk factor for chronic hand dermatitis, which can be seen in children too. Pimecrolimus cream 1% is approved to treat atopic dermatitis in children aged 2 years or older. In adults, this drug has been used for some clinical indications other than atopic dermatitis, such as chronic hand dermatitis. Here, we describe an adverse drug reaction in a 2-year-old child affected with atopic dermatitis, who was treated with topical pimecrolimus in order to ameliorate her concomitant hand dermatitis. The use of topical pimecrolimus led to a previously undescribed hand pustular dermatosis, being consistent with a form of pustular leukocytoclastic vasculitis, which required the permanent discontinuation of topical pimecrolimus.

U2 - 10.5863/1551-6776-21.1.81

DO - 10.5863/1551-6776-21.1.81

M3 - Article

VL - 21

SP - 81

EP - 84

JO - Journal of Pediatric Pharmacology and Therapeutics

JF - Journal of Pediatric Pharmacology and Therapeutics

SN - 1551-6776

IS - 1

ER -